Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting

April 27, 2023

https://www.globenewswire.com/news-release/2023/04/26/2655762/0/en/Tempest-Announces-TPST-1495-Poster-Presentation-at-the-2023-ASCO-Annual-Meeting.html

BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) — Tempest Therapeutics, Inc. (Nasdaq:TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted and immune-mediated mechanisms, today announced the acceptance of an abstract on TPST-1495, a EP2/EP4 prostaglandin receptor dual antagonist, for a poster presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting taking place June 2-6, 2023 at the McCormick Place Convention Center in Chicago, IL.

Read more at globenewswire.com

Related news for (TPST)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.